Payment overview · 2025
General Payments
$183.61
10 reported records · 6 companies
Healthcare provider profile · identity verified
Jason A Torrente, DO
Allopathic & Osteopathic Physicians|Family Medicine · HAMILTON, NJ · NPI 1679514723
Verified facts
What the public records show
CMS Open Payments records show Jason A Torrente, DO received $183.61 in general payments during 2025 across 10 reported records.
Exact Sciences Corporation accounted for 46.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
Bavarian Nordic A/S reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JYNNEOS as an associated drug or biological on 13 records involving 13 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jynneos by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GARDASIL 9 as an associated drug or biological on 35573 records involving 25304 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Gardasil 9 by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VAQTA as an associated drug or biological on 1592 records involving 1446 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Vaqta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $85.93 | 46.8% | 4 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.18 | 15.3% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $20.53 | 11.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.07 | 9.3% | 1 | 2025 |
| Bavarian Nordic A/S | Unresolved — no canonical attribution shown | $16.69 | 9.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.21 | 8.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $183.61 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $43.75 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $28.18 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| Vivotif Normalized: vivotif |
Drug | Bavarian Nordic A/S | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bavarian Nordic A/S Exact reporting entity; no affiliate inference |
2025 | JYNNEOS open payments reported associated product |
CMS Open Payments — General Payments 13 supporting records · 13 recipient NPIs · example record 1250212537 |
Jynneos · 2024 Exact normalized brand match · 1 Part D row |
42 | 31 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | GARDASIL 9 open payments reported associated product |
CMS Open Payments — General Payments 35573 supporting records · 25304 recipient NPIs · example record 1237992212 |
Gardasil 9 · 2024 Exact normalized brand match · 1 Part D row |
119 | 83 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VAQTA open payments reported associated product |
CMS Open Payments — General Payments 1592 supporting records · 1446 recipient NPIs · example record 1237992242 |
Vaqta · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 66804 | 48994 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 44697 | 44543 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 24935 | 24861 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 21732 | 21625 |
| Twinrix | Hepatitis A And B Vaccine/Pf | 1111 | 742 |
| Havrix | Hepatitis A Virus Vaccine/Pf | 756 | 675 |
| Typhim Vi | Typhoid Vi Polysacch Vaccine | 336 | 335 |
| M-M-R Ii Vaccine | Measles,mumps,rubella Vacc/Pf | 257 | 249 |
| Tenivac | Tetanus-Diphtheria Toxoids/Pf | 185 | 185 |
| Gardasil 9 | Hpv Vaccine 9-Valent/Pf | 119 | 83 |
| Yf-Vax | Yellow Fever Vaccine Live/Pf | 108 | 108 |
| Menquadfi | Mening Vac A,c,y,w135,c-Tet/Pf | 97 | 93 |
| Ipol | Poliomyelitis Vaccine, Killed | 69 | 63 |
| Priorix | Measles,mumps,rubella Vacc/Pf | 63 | 59 |
| Heplisav-B | Hepatitis B Vaccine/Cpg1018/Pf | 52 | 38 |
| Varivax Vaccine | Varicella Vaccine Live/Pf | 45 | 41 |
| Jynneos | Smallpox And Mpox Live Vacc/Pf | 42 | 31 |
| Menveo A-C-Y-W-135-Dip | Mening Vac A,c,y,w-135 Dip/Pf | 30 | 29 |
| Ixiaro | Japanese Encephalitis Vacc/Pf | 27 | 17 |
| Vaqta | Hepatitis A Virus Vaccine/Pf | 27 | 27 |
| Tdvax | Tetanus, Diphtheria Tox,adult | 25 | 25 |
| Engerix-B Adult | Hepatitis B Virus Vaccine/Pf | 19 | 12 |
| Imovax Rabies Vaccine | Rabies Vacc, Human Diploid/Pf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $183.61 · 10 records | Exact Sciences Corporation | Cologuard Collection Kit, LAGEVRIO, MOUNJARO, NUZYRA, SKYCLARYS, The Cologuard Plus Collection Kit, VERQUVO, Vivotif, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Bavarian Nordic A/S?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error